What is the recommended week-by-week titration schedule for eplerenone and spironolactone?

Week-by-Week Titration of Eplerenone and Spironolactone

For heart failure with reduced ejection fraction (HFrEF), start spironolactone or eplerenone at 25 mg once daily, then increase to 50 mg once daily after 4 weeks if tolerated, with potassium and renal function monitoring at 1 week, 4 weeks, then every 6 months thereafter. 123

Eplerenone Titration Schedule

Heart Failure Post-MI / HFrEF Context

Week 0 (Baseline):

• Check serum potassium (must be <5.0 mEq/L) and eGFR (must be >30 mL/min/1.73 m²)
• Start eplerenone 25 mg once daily 2

Week 1:

• Measure serum potassium and creatinine 12
• Adjust dose based on potassium levels (see monitoring table below)

Week 4:

• Measure serum potassium and creatinine 12
• Increase to target dose of 50 mg once daily if potassium <5.0 mEq/L and patient tolerates initial dose 24

Ongoing:

• Monitor potassium and renal function every 6 months if stable 1
• More frequent monitoring if clinical instability

Hypertension Context

Week 0:

• Start eplerenone 50 mg once daily 2

Week 4:

• If BP inadequately controlled, increase to 50 mg twice daily (maximum 100 mg/day) 2
• Higher doses not recommended due to increased hyperkalemia risk without additional BP benefit 2

Spironolactone Titration Schedule

Heart Failure Context

Week 0 (Baseline):

• Check serum potassium (must be ≤5.0 mEq/L) and eGFR (must be >30 mL/min/1.73 m²)
• Start 25 mg once daily if eGFR >50 mL/min/1.73 m² 3
• Start 25 mg every other day if eGFR 30-50 mL/min/1.73 m² due to hyperkalemia risk 3

Week 1:

• Measure serum potassium and creatinine 1

Week 4:

• Measure serum potassium and creatinine 1
• Increase to 50 mg once daily if tolerated and potassium remains ≤5.0 mEq/L 3

Ongoing:

• Monitor potassium and renal function every 6 months if stable 1

Primary Aldosteronism Context (Per Endocrine Society Guidelines)

The titration is more gradual for primary aldosteronism:

Week 0:

• Start spironolactone 12.5-25 mg/day (or eplerenone 25 mg daily/twice daily) 5
• For severe PA with profound hypokalemia, consider higher initial dose: spironolactone 50 mg/day or eplerenone 50 mg twice daily 5

Weeks 2-3:

• Measure electrolytes, renal function, and renin 5
• Discontinue or reduce potassium supplements by days 2-4 as normokalemia typically occurs within 3-5 days 5

Weeks 8-12:

• Reassess BP, electrolytes, renal function, and renin 5
• Increase spironolactone in 25-50 mg increments or eplerenone in 25-100 mg increments if BP not controlled 5

Weeks 16-24:

• Continue dose adjustments at 8-12 week intervals 5
• Full drug effect may take up to 3 months in severe PA 5
• Most patients achieve renin de-suppression with spironolactone 50-100 mg/day 5

Critical Monitoring and Dose Adjustments Based on Potassium

For Heart Failure (Both Drugs):

Serum Potassium (mEq/L)	Action
<5.0	Continue current dose or uptitrate
5.0-5.4	No adjustment needed
5.5-5.9	Reduce dose (50 mg→25 mg daily, or 25 mg daily→25 mg every other day) [2]
≥6.0	Withhold drug; restart at 25 mg every other day when K+ <5.5 mEq/L [2]

Critical safety note: If potassium cannot be maintained <5.5 mEq/L, discontinue MRA to avoid life-threatening hyperkalemia 1

Key Differences Between the Two Drugs

Spironolactone:

• More potent MRA but less selective 4
• Higher risk of gynecomastia (dose-related, appears 1-2 months to ≥6 months) 54
• Stronger evidence for resistant hypertension 6
• Lower cost (generic available)

Eplerenone:

• More selective for mineralocorticoid receptor 4
• Significantly lower risk of gynecomastia and treatment withdrawal 7
• May show superior cardiovascular mortality reduction in some analyses 7
• Requires twice-daily dosing for hypertension
• More expensive

Common Pitfalls to Avoid

1. Starting MRA with baseline potassium ≥5.0 mEq/L - This dramatically increases hyperkalemia risk 1

2. Inadequate monitoring frequency - Must check potassium at 1 week, not just at 4 weeks, as hyperkalemia can develop rapidly 12

3. Continuing MRA when eGFR <30 mL/min/1.73 m² - Both drugs are partially renally excreted and risk accumulation 1

4. Not reducing potassium supplements early - In primary aldosteronism, supplements should be reduced/stopped by days 2-4 as normokalemia occurs quickly 5

5. Ignoring drug interactions - When patients start ACE inhibitors, ARBs, or NSAIDs, recheck potassium and creatinine within 3-7 days 2

6. For moderate CYP3A inhibitors (erythromycin, fluconazole, verapamil): Do not exceed eplerenone 25 mg once daily in HF patients 2

7. Expecting immediate BP response in primary aldosteronism - Full effect takes 8-12 weeks, sometimes up to 3 months 5

8. Not addressing dietary sodium - High salt intake is a very common reason for apparent MRA non-response; target <85.5 mmol/day sodium (<5 g/day salt) 5